EP3820487A4 - Gene editing for autoimmune disorders - Google Patents

Gene editing for autoimmune disorders Download PDF

Info

Publication number
EP3820487A4
EP3820487A4 EP19803321.9A EP19803321A EP3820487A4 EP 3820487 A4 EP3820487 A4 EP 3820487A4 EP 19803321 A EP19803321 A EP 19803321A EP 3820487 A4 EP3820487 A4 EP 3820487A4
Authority
EP
European Patent Office
Prior art keywords
autoimmune disorders
gene editing
editing
gene
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19803321.9A
Other languages
German (de)
French (fr)
Other versions
EP3820487A1 (en
Inventor
Matthew Rabinowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Themba Inc
Original Assignee
Themba Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Themba Inc filed Critical Themba Inc
Publication of EP3820487A1 publication Critical patent/EP3820487A1/en
Publication of EP3820487A4 publication Critical patent/EP3820487A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP19803321.9A 2018-05-14 2019-05-14 Gene editing for autoimmune disorders Pending EP3820487A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862762708P 2018-05-14 2018-05-14
PCT/US2019/032214 WO2019222212A1 (en) 2018-05-14 2019-05-14 Gene editing for autoimmune disorders

Publications (2)

Publication Number Publication Date
EP3820487A1 EP3820487A1 (en) 2021-05-19
EP3820487A4 true EP3820487A4 (en) 2022-03-09

Family

ID=68540991

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19803321.9A Pending EP3820487A4 (en) 2018-05-14 2019-05-14 Gene editing for autoimmune disorders

Country Status (4)

Country Link
EP (1) EP3820487A4 (en)
JP (1) JP2021523943A (en)
CN (1) CN112384230A (en)
WO (1) WO2019222212A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220339192A1 (en) * 2019-09-07 2022-10-27 Themba Inc. Gene editing for viral infections
US20230223102A1 (en) * 2020-03-31 2023-07-13 Themba Inc. Genetic model validation methods
WO2022175674A1 (en) * 2021-02-19 2022-08-25 Oxford University Innovation Limited Modified human cells and uses thereof in the treatment of immune-mediated diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018035388A1 (en) * 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2018064208A1 (en) * 2016-09-28 2018-04-05 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016049251A1 (en) * 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
WO2017066561A2 (en) * 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
AU2017230011A1 (en) * 2016-03-11 2018-09-27 2Seventy Bio, Inc. Genome edited immune effector cells
WO2018022473A1 (en) * 2016-07-25 2018-02-01 Wave Life Sciences Ltd. Phasing
CA3034094A1 (en) * 2016-08-16 2018-02-22 Bluebird Bio, Inc. Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use
US20190291916A1 (en) * 2016-08-16 2019-09-26 Mars, Incorporated Open-walled pack
EP3510157B1 (en) * 2016-09-08 2023-05-31 2seventy bio, Inc. Pd-1 homing endonuclease variants, compositions, and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018035388A1 (en) * 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2018064208A1 (en) * 2016-09-28 2018-04-05 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GLOCKER ERIK-OLIVER ET AL: "IL-10 and IL-10 receptor defects in humans : IL-10/IL-10R deficiency", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 1246, no. 1, 1 December 2011 (2011-12-01), US, pages 102 - 107, XP055883124, ISSN: 0077-8923, DOI: 10.1111/j.1749-6632.2011.06339.x *
HUANG HAILIANG ET AL: "Fine-mapping inflammatory bowel disease loci to single-variant resolution", NATURE, vol. 547, no. 7662, 1 July 2017 (2017-07-01), London, pages 173 - 178, XP055882978, ISSN: 0028-0836, Retrieved from the Internet <URL:https://www.nature.com/articles/nature22969.pdf> DOI: 10.1038/nature22969 *
See also references of WO2019222212A1 *
SIVANESAN DURGA ET AL: "IL23R (Interleukin 23 Receptor) Variants Protective against Inflammatory Bowel Diseases (IBD) Display Loss of Function due to Impaired Protein Stability and Intracellular Trafficking", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 291, no. 16, 1 April 2016 (2016-04-01), US, pages 8673 - 8685, XP055883125, ISSN: 0021-9258, DOI: 10.1074/jbc.M116.715870 *

Also Published As

Publication number Publication date
CN112384230A (en) 2021-02-19
EP3820487A1 (en) 2021-05-19
WO2019222212A1 (en) 2019-11-21
JP2021523943A (en) 2021-09-09

Similar Documents

Publication Publication Date Title
EP3894550A4 (en) Novel crispr-cas systems for genome editing
EP3765605A4 (en) Use of morphogenic factors for the improvement of gene editing
EP3781705A4 (en) Compositions and methods for gene editing
EP3768327A4 (en) Gene editing for autosomal dominant diseases
EP3870273A4 (en) Current source for neurostimulation
EP3773572A4 (en) Rimegepant for cgrp related disorders
EP3703712A4 (en) Primary cell gene editing
EP3844692A4 (en) E-hailing service
EP3805381A4 (en) Phytase mutant
EP3843739A4 (en) Novel methods
EP3781677A4 (en) Compositions and methods for improved gene editing
EP3765021A4 (en) Novel methods
EP3738063A4 (en) Methods for securing data
EP3784528A4 (en) In-module media assembly
EP3887396A4 (en) Gene therapies for neurodegenerative disease
IL282752A (en) Methods for altering gene expression for genetic disorders
EP3966335A4 (en) Improved gene editing system
EP3801527A4 (en) Novel methods
EP3820487A4 (en) Gene editing for autoimmune disorders
EP3843738A4 (en) Novel methods
EP3864161A4 (en) Regulated gene editing system
EP3788535A4 (en) Techniques for performing secure operations
EP3887514A4 (en) Therapeutic gene editing for elane-associated disease
EP3814370A4 (en) Nucleases for genome editing
EP3782842A4 (en) Pantograph

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201113

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220204

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0781 20100101ALI20220131BHEP

Ipc: C07K 16/28 20060101ALI20220131BHEP

Ipc: A61K 35/28 20150101ALI20220131BHEP

Ipc: A61K 35/17 20150101AFI20220131BHEP